文献速递结核与非结核分枝杆菌

老年肺结核治疗结局:西雅图与金县研究

Tuberculosis in Older Adults: Seattle and King County, Washington.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究纳入2009–2014年华盛顿州金县403例肺结核成人患者,其中111例≥65岁。老年患者影像空洞较少,但治疗完成率更低(76.6% vs 94.9%,P<.0001)、治疗期间死亡率更高(18.9% vs 2.1%,P<.0001),≥75岁者更易出现药物不良事件且发生时间更晚。

要点

  • ≥65岁肺结核患者治疗完成率显著低于年轻患者。
  • ≥65岁患者治疗期间死亡风险显著升高,≥75岁更明显。
  • 吡嗪酰胺是各年龄段多数药物不良反应的原因。

核心结论

  • ≥65岁肺结核患者病情相对不进展但治疗并发症风险更高,死亡与不良事件风险在≥75岁者中最突出。

研究设计与样本

  • 回顾性研究,评估2009–2014年华盛顿州金县诊断为肺结核的成人患者,共403例,其中111例≥65岁。

主要发现

  • ≥65岁患者胸部影像空洞显著更少。
  • ≥65岁患者完成抗结核治疗比例76.6%,低于年轻患者的94.9%(P<.0001)。
  • ≥65岁患者治疗期间死亡比例18.9%,高于年轻患者的2.1%(P<.0001)。
  • ≥75岁患者较<75岁者更易发生归因于抗结核药物的不良事件,且不良事件更常出现在治疗后期。
  • 无论年龄,吡嗪酰胺是多数不良反应的原因。

临床怎么用

  • 对≥65岁肺结核患者应加强治疗期间监测,尤其关注死亡与药物不良事件风险。
  • 对≥75岁患者需警惕治疗后期出现的药物不良事件。
  • 使用含吡嗪酰胺方案时应重点监测相关不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the United States, tuberculosis (TB) incidence rates are highest among adults aged ≥65 years. We performed this study to evaluate outcomes of older patients undergoing treatment for TB disease, including the frequency of adverse events related to TB treatment. METHODS: This study evaluated adult patients who were diagnosed with pulmonary TB from 2009 to 2014 in King County, Washington. Patient characteristics, manifestation of TB, and treatment outcomes in different age groups were compared. Frequency and type of adverse events that resulted in treatment interruption were evaluated and patients aged ≥65 years were compared with selected younger patients. RESULTS: There were 403 patients who met the study criteria, 111 of whom were aged ≥65 years. Older patients were significantly less likely to have cavitation on chest radiographs. Patients aged ≥65 years were less likely to complete TB treatment (76.6% vs 94.9%, P < .0001) and were more likely to die during treatment (18.9% vs 2.1%, P < .0001). The difference in these outcomes was heightened for those aged ≥75 years compared with those aged <75 years. Those aged ≥75 years were also more likely to have an adverse event attributable to TB medication and were more likely to have an adverse event later in therapy. Regardless of age, pyrazinamide was responsible for the majority of adverse reactions. CONCLUSIONS: Adults aged ≥65 years with pulmonary TB had less-advanced disease but a higher risk of complications during treatment such as death or adverse events. This effect was most pronounced among those aged ≥75 years.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gardner Toren K, Spitters C, Pecha M, et al. Tuberculosis in Older Adults: Seattle and King County, Washington. Clin Infect Dis. 2020. PMID: 30977788. doi:10.1093/cid/ciz306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。